Dr. Patrick Forde, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
401 North Broadway, Weinberg Bdg.
Baltimore, MD 21231
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 78
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license UNLICENSED
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 158
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 193 | 93 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 58 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Hospital discharge day management, more than 30 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 36 |
| Prochlorperazine Maleate Other prescribers in Baltimore, MD | 16 |
| Xalkori (crizotinib) | 14 |
| Tamsulosin Hcl Other prescribers in Baltimore, MD | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 31 payments worth $41,900 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $13,035 |
|---|---|
| AstraZeneca UK Limited | $6,989 |
| E.r. Squibb & Sons, L.l.c. | $6,194 |
| AbbVie Inc. | $4,516 |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,430 |
| Novocure Inc. | $2,800 |
| Amgen Inc. | $2,058 |
| Lantheus Medical Imaging, Inc. | $788 |
| Consulting Fee | $37,978 |
|---|---|
| Honoraria | $2,800 |
| Food and Beverage | $601 |
| Travel and Lodging | $522 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Apr 16, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $9,933 |
| AstraZeneca UK Limited Feb 12, 2025 | Consulting Fee ENHERTU · Oncology Company’s descriptionResearch Related Service | $4,510 |
| AbbVie Inc. Jun 13, 2025 | Consulting Fee | $4,350 |
| E.r. Squibb & Sons, L.l.c. May 27, 2025 | Consulting Fee | $4,165 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 21, 2025 | Consulting Fee ALUNBRIG · ONCOLOGY | $2,905 |
| Novocure Inc. May 23, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $2,800 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Consulting Fee | $2,460 |
| Amgen Inc. Apr 1, 2025 | Consulting Fee IMDELLTRA (AMG757) · Hematology | $2,058 |
| AstraZeneca UK Limited Apr 14, 2025 | Consulting Fee | $2,050 |
| E.r. Squibb & Sons, L.l.c. Sep 19, 2025 | Consulting Fee | $1,910 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee | $781 |
| AstraZeneca UK Limited Dec 1, 2025 | Consulting Fee | $350 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Travel and Lodging travel to Philadelphia, PA Company’s descriptionConsulting Expenses | $399 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 21, 2025 | Consulting Fee ALUNBRIG · ONCOLOGY | $2,905 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 21, 2025 | Travel and Lodging ALUNBRIG · ONCOLOGY · travel to BERLIN, Germany · in-kind | $55.51 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 21, 2025 | Travel and Lodging ALUNBRIG · ONCOLOGY · travel to BERLIN, Germany · in-kind | $34.14 |
| Lantheus Medical Imaging, Inc. Nov 12, 2025 | Consulting Fee | $788 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Consulting Fee | $2,460 |
| E.r. Squibb & Sons, L.l.c. Sep 19, 2025 | Consulting Fee | $1,910 |
| Dr.reddy's Laboratories,inc. Jul 14, 2025 | Consulting Fee | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 25, 2025 | Consulting Fee | $775 |
| AbbVie Inc. Jun 13, 2025 | Consulting Fee | $4,350 |
| AbbVie Inc. Jun 13, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $33.32 |
| E.r. Squibb & Sons, L.l.c. May 27, 2025 | Consulting Fee | $4,165 |
| Novocure Inc. May 23, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $2,800 |
| AstraZeneca Pharmaceuticals LP Apr 16, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $9,933 |
| AstraZeneca UK Limited Apr 14, 2025 | Consulting Fee | $2,050 |
| Amgen Inc. Apr 1, 2025 | Consulting Fee IMDELLTRA (AMG757) · Hematology | $2,058 |
| AstraZeneca UK Limited Feb 12, 2025 | Consulting Fee ENHERTU · Oncology Company’s descriptionResearch Related Service | $4,510 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 6, 2025 | Consulting Fee | $633 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $507,965 in research payments for these studies, mostly to the institutions running them.
- An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1 PD-L1 Containing Therapy HUDSON
AstraZeneca Pharmaceuticals LP - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Regeneron Pharmaceuticals, Inc. · Terminated · NCT04982224
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.